Skip to main
BEAT

HeartBeam (BEAT) Stock Forecast & Price Target

HeartBeam (BEAT) Analyst Ratings

Based on 4 analyst ratings
Strong Buy
Strong Buy 100%
Buy 0%
Hold 0%
Sell 0%
Strong Sell 0%

Bulls say

HeartBeam is a medical technology company with a proprietary vector ECG system that captures multi-dimensional electrical signals from the heart and synthesizes them into a 12-lead ECG, enabling more accurate interpretation by physicians. The company has received FDA clearance for its ECG solutions and is targeting a large, multi-billion-dollar market for remote patient monitoring and ambulatory ECG solutions. HeartBeam's strategy to initially target concierge and specialty medicine practices, with plans to expand to direct-to-consumer markets, could lead to a substantial increase in annual revenue. Additionally, the company is incorporating artificial intelligence into its platform to expand its capabilities and could potentially unlock additional market opportunities through its technology.

Bears say

HeartBeam is facing challenges in terms of market opportunity due to high competition and slow adoption of remote and digital healthcare solutions, leading to potential revenue growth issues. Additionally, the company's dependence on a highly recurring, subscription-based revenue model with strong retention could be impacted by delays or unfavorable outcomes in regulatory and clinical processes, as well as slower-than-expected physician adoption and market development. Despite a differentiated intellectual property portfolio, HeartBeam may face pressure from established players in the cardiac monitoring space, potentially limiting its competitive positioning and revenue potential.

HeartBeam (BEAT) has been analyzed by 4 analysts, with a consensus rating of Strong Buy. 100% of analysts recommend a Strong Buy, 0% recommend Buy, 0% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of HeartBeam and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About HeartBeam (BEAT) Forecast

Analysts have given HeartBeam (BEAT) a Strong Buy based on their latest research and market trends.

According to 4 analysts, HeartBeam (BEAT) has a Strong Buy consensus rating as of May 5, 2026. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $5.62, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $5.62, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

HeartBeam (BEAT)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.